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Abstract
Background: Approximately 15% of primary colorectal cancers have DNA mismatch repair deficiency, causing a
complex genome with thousands of small mutations—the microsatellite instability (MSI) phenotype. We
investigated molecular heterogeneity and tumor immunogenicity in relation to clinical endpoints within this
distinct subtype of colorectal cancers.
Methods: A total of 333 primary MSI+ colorectal tumors from multiple cohorts were analyzed by multilevel
genomics and computational modeling—including mutation profiling, clonality modeling, and neoantigen
prediction in a subset of the tumors, as well as gene expression profiling for consensus molecular subtypes (CMS)
and immune cell infiltration.
Results: Novel, frequent frameshift mutations in four cancer-critical genes were identified by deep exome sequencing,
including in CRTC1, BCL9, JAK1, and PTCH1. JAK1 loss-of-function mutations were validated with an overall frequency of
20% in Norwegian and British patients, and mutated tumors had up-regulation of transcriptional signatures associated
with resistance to anti-PD-1 treatment. Clonality analyses revealed a high level of intra-tumor heterogeneity; however,
this was not associated with disease progression. Among the MSI+ tumors, the total mutation load correlated
with the number of predicted neoantigens (P = 4 × 10−5), but not with immune cell infiltration—this was
dependent on the CMS class; MSI+ tumors in CMS1 were highly immunogenic compared to MSI+ tumors in
CMS2-4. Both JAK1 mutations and CMS1 were favorable prognostic factors (hazard ratios 0.2 [0.05–0.9] and 0.4 [0.2–0.9],
respectively, P = 0.03 and 0.02).
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Conclusions: Multilevel genomic analyses of MSI+ colorectal cancer revealed molecular heterogeneity with clinical
relevance, including tumor immunogenicity and a favorable patient outcome associated with JAK1 mutations and the
transcriptomic subgroup CMS1, emphasizing the potential for prognostic stratification of this clinically important
subtype.
Keywords: Colorectal cancer, Consensus molecular subtypes, Immunogenicity, Immunotherapy resistance, JAK1,
Microsatellite instability, Mutation, Neoantigen, Prognosis
Background
Colorectal cancers (CRCs) with the microsatellite in-
stability (MSI) phenotype are defined by high rates of in-
sertions and deletions (indels) of nucleotides in short,
repetitive sequences [1–3]. This is caused by a defective
DNA mismatch repair (MMR) machinery, either by epi-
genetic silencing, primarily of MLH1 [4–6], or through
somatic or germ line mutations [7–11]. MSI occurs in a
wide range of cancer types but is prevalent in only a few
[12–15]. In CRC, the MSI+ subgroup accounts for ap-
proximately 15% of cases and is characterized by a low
level of DNA copy number aberrations but a higher fre-
quency of small mutations (single nucleotide variants
(SNVs), and indels) than most other types of cancer [16,
17]. The mutation profiles of MSI+ CRCs differ from
those of microsatellite stable (MSS) CRCs, for example,
by a strong enrichment for BRAF mutations [18]. Fur-
thermore, low complexity sequences with short tandem
repeats are prone to indel mutations and are found in
the coding regions of several cancer-critical genes [19–
21], including TGFBR2, which was the first MSI target
gene to be discovered [22–24]. However, large-scale ana-
lysis of indel mutations has been challenging [25, 26],
and a recent paper describing frameshift mutations in
RNF43 in 80% of MSI+ CRCs clearly demonstrates that
even highly prevalent indel mutations have gone un-
noticed [27].
CRC has a high world-wide incidence and mortality
rate [28], but compared with the MSS subgroup, patients
with MSI+ tumors have a favorable prognosis in the pri-
mary setting [3, 29, 30]. This is possibly explained by
tumor immunogenicity and the high level of lymphocyte
infiltration [31, 32]. Immunogenicity in MSI+ tumors
may be a result of the high mutation load and subse-
quent expression of mutated, tumor-specific peptides as
neoantigens [33]. Neoantigens are presented on the
tumor cell surface by class I HLA molecules and have
the potential to activate cytotoxic T cells. Expression of
neoantigens, computationally predicted based on muta-
tion profiling, has been shown to be associated with a fa-
vorable patient outcome across tumor types [34]. In
CRC, there are strong indications that the number of
predicted neoantigens is also prognostic [35–37], but the
subgroup of MSI+ tumors has not been specifically
analyzed in this context. In the metastatic setting, MSI+
tumors are associated with a poor prognosis [38], but
patients generally respond well to immunotherapy by
anti-PD-1 immune checkpoint inhibition [39]. However,
disease control is not obtained in all cases, and predic-
tion of treatment response is currently a research area of
high interest [40, 41].
At the gene expression level, an international consor-
tium has recently described four consensus molecular
subtypes (CMS) of CRC [42]. The majority of MSI+
tumors are found in CMS1, which is a subtype charac-
terized by a high mutation load and infiltration of im-
mune cells in the tumor microenvironment [42, 43].
CMS classification has clinical value independent of can-
cer stage, and patients with mesenchymal CMS4 tumors
have a poor outcome, while CMS1 is associated with a
poor patient survival after relapse. The heterogeneity
and clinical value of CMS classification specifically
within the subgroup of MSI+ tumors remains unknown.
In the present study, we have performed deep exome
sequencing of MSI+ CRCs, integrated with DNA copy
number and gene expression analyses, to (i) identify po-
tential novel mutations and (ii) analyze the mutation-
associated immunogenicity of the tumors, in relation to
both CMS and clinical endpoints.
Methods
Patient samples
A total of 333 primary MSI+ CRCs from five patient
series were analyzed for mutations, DNA copy number,
and/or gene expression (Fig. 1a). This includes tumors
from two Norwegian series (n = 78 and 31) and British
patients recruited to the VICTOR adjuvant randomized
trial (n = 83, 81 with clinical annotation available) [44],
as well as publicly available data from The Cancer
Genome Atlas (TCGA; n = 66) [16] and a French multi-
center cohort (n = 75; Gene Expression Omnibus (GEO),
accession number GSE39582) [45].
Fresh-frozen tumor specimens and matched normal
colonic mucosa have consecutively been collected from
patients treated for primary CRC at Oslo University
Hospital, Norway since 2005. This patient series is re-
ferred to as Norwegian series I and all 78 patients
treated for MSI+ CRC before May 2013 were included.
Sveen et al. Genome Medicine  (2017) 9:46 Page 2 of 16
For validation of JAK1 mutation prevalence, another 31
MSI+ tumors from an anonymized Norwegian CRC pa-
tient series treated surgically at hospitals in the Oslo re-
gion from 1987 to 1989 were analyzed (Norwegian series
II; Table 1; Fig. 1a).
DNA was extracted using a standard phenol/chloroform
protocol or a magnetic bead approach according to the
manufacturer’s recommendations (Maxwell 16 DNA
Purification Kit; Promega, Madison, WI, USA). Microsat-
ellite instability status of the tumors was determined using
the consensus markers provided by the National Cancer
Institute (Bethesda marker panel), as previously described
[46]. The DNA promoter methylation status ofMLH1 was
analyzed by quantitative methylation-specific PCR, as
previously described [47]. Primers and probe (Additional
file 1: Table S1) were designed using the Methyl Primer
Express 1.0 and the Primer Express 3.0 software (Thermo
Fisher Scientific Inc., Waltham, MA, USA). RNA was
extracted using the Qiagen Allprep DNA/RNA/miRNA
Universal kit, according to the manufacturer’s instructions
(Qiagen, GmBH, Hilden, Germany).
Exome sequencing and mutation analysis
Matched tumor and normal colonic mucosa samples from
33 patients in Norwegian series I were exome sequenced
(Table 1; Fig. 1a). Exome libraries were generated from
1 μg of genomic DNA using the Agilent SureSelectXT
Human All Exon V5 kit (Agilent, Santa Clara, CA, USA),
and 2 × 100-base-pair paired-end sequencing was per-
formed using the Illumina HiSeq 2500 system and
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Fig. 1 Patient samples and data analyses. a A total of 333 MSI+ CRCs were analyzed, including 192 in-house tumor samples and publicly available
data from 141 patients; 248 were analyzed for gene mutations and 213 for gene expression. Among the 68 samples in Norwegian series I
analyzed for JAK1 mutations by PCR-based analysis, 33 were exome sequenced, 27 were analyzed for DNA copy number aberrations, and 63 were
analyzed for gene expression. b Molecular result parameters are shown in red, clinical endpoints in green, and the data types used for analysis in
grey. Significant associations are indicated by red arrows and the red cross indicates no association
Table 1 Clinicopathological data for MSI+ CRCs analyzed in-lab
Clinicopathological
parameters
Norwegian series I (n = 78) Norwegian
series II
(n = 31)
VICTOR
(n = 81)
All patients Exome sequenced
(n = 33)
Patient age at diagnosis (years)
Mean 75 74 66 65
Min 37 37 26 38
Max 93 93 92 89
Patient gender
Female 55 23 18 45
Male 23 10 13 36
Tumor localization
Right 68 31 20 66
Left 6 1 7 13
Rectum 4 1 4 -
Unknown - - - 2
Tumor stage
I 16 1 3 -
II 42 23 17 54
III 15 9 8 27
IV 5 - 3 -
5-year survival rates
Overall 71% 85% 83% 82%
Relapse-free 70% 82% 72% NA
NA not available
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sequencing by synthesis chemistry (Illumina, San Diego,
CA, USA) at the Oslo University Hospital Genomics Core
Facility (The Norwegian Radium Hospital, Oslo, Norway).
We received the sequencing reads and performed se-
quence alignment using BWA version 0.7.8 [48]. Sequence
Alignment Map (SAM) files were converted to Binary
Alignment Map (BAM) files using Picard version 1.102
(http://broadinstitute.github.io/picard/). SAMtools version
0.1.19 (http://samtools.sourceforge.net/) was used for
sorting and indexing. The Picard toolbox was applied
to remove duplicates. Subsequent refinements of the
BAM files were done according to The Genome
Analysis Toolkit Best Practices guidelines (https://
www.broadinstitute.org/gatk/guide/best-practices). Po-
tential indel regions were realigned using IndelRealigner
and the quality of the alignment was recalibrated using
BaseRecalibrator and AnalyzeCovariates. All SNVs were
called using MuTect v.1.1.7 [49] and indels were scored
using the program Strelka v.1.0.14 [50]. The sequence var-
iants were annotated using ANNOVAR [51] and the
Ensembl Variant Effect Predictor v.79. The coverage
threshold for each candidate somatic mutation was set to
minimum 10× for normal tissue and 15× for tumor
samples, and loci where <5% of the reads supported a
mutation were filtered out. A single mutated read
from the normal tissue was accepted to allow for mi-
nute sample contamination or the presence of circu-
lating tumor cells. All analyses were done using
human genome build hg19.
Significance of candidate mutations was evaluated using
MutSigCV v.1.4 [52], and genes with a false discovery rate
(q value) below 0.05 were considered significantly mutated
above the background mutation rate. For comparison, the
Cancer Gene Census (CGC) v.73 was downloaded from
the COSMIC database (http://cancer.sanger.ac.uk/census),
and the 571 listed genes are referred to as cancer-critical
genes.
Candidate genes with novel frequent indels were add-
itionally screened for hotspot indels in homopolymeric
regions using the SAMtools (v.0.1.19) mpileup com-
mand. For in silico validation, aligned exome sequencing
data from 78 MSI+ CRCs in TCGA were downloaded
from the Cancer Genomics Hub. Using a threshold of a
minimum of seven reads at each homopolymer with a
mutation hotspot, 66 tumors were retained for mutation
analyses using the SAMtools mpileup command. The
mutation load (total number of mutations) was deter-
mined for 60 of the tumors using the same analysis pipe-
line as for the in-house exome sequencing data.
Estimation of MSI level
The level of MSI per sample was estimated from the ex-
ome sequencing data using the algorithm MSIsensor [53]
with default settings. For a catalogue of microsatellites in
the reference genome (homopolymers of a minimum
of 5 base pairs and microsatellites with maximum re-
peat unit length 5), the number of loci with sufficient
sequencing coverage to be scored per sample (mini-
mum 20 reads) was detected by mapping sequencing
reads from BAM files. Unstable microsatellites were
detected by counting mapped reads with non-reference
repeat lengths, and somatic events were detected as
sites with significantly different mutant read count dis-
tributions between paired tumor–normal samples. An
MSI score was calculated per tumor, representing the
percentage of unstable microsatellites (microsatellites
with indels). The MSI score was not associated with
the number of microsatellites scored per sample
(Spearman correlation −0.03, P = 0.8).
Mutation signatures
The mutation signatures designated in COSMIC [54] were
analyzed per tumor based on SNVs and their sequence
context, considering the immediately flanking 5′ and 3′
nucleotides using the R package SomaticSignatures [55]
with default settings.
PCR-based validation of JAK1 indels in independent
patient series
Frameshift mutations in four hotspots in homopolymeric
regions of JAK1 were analyzed by PCR-based fragment
analyses in a total of 182 MSI+ CRCs (Fig. 1a). Fluores-
cently labeled primers were designed using Primer3 [56]
(Additional file 1: Table S1). The four JAK1 fragments
were amplified in multiplex PCR using the Qiagen
Multiplex PCR Kit according to the manufacturer’s rec-
ommendations. One primer per fragment was labeled
with a fluorescent dye from the G5 dye set, and GS500
LIZ was used as a size standard (Thermo Fisher
Scientific Inc.). All fragments were run in duplicate on
an ABI 3730 DNA Analyzer, with default Microsatellite
Analysis settings, and analyzed by the GeneMapper soft-
ware v.3.7 (Thermo Fisher Scientific Inc.). DNA from
disease-free individuals and water served as normal and
negative controls, respectively. Electropherograms were
scored independently by two researchers.
High resolution DNA copy number analysis
DNA copy number data were generated for 27 of the 33
exome sequenced MSI+ tumors in Norwegian series I
using Affymetrix Genome-Wide Human SNP Arrays 6.0
(Affymetrix Inc., Santa Clara, CA; Fig. 1a). DNA (1 μg)
was prepared according to the Affymetrix SNP6.0 Cyto-
genetics Copy Number Assay (revision 3) and hybridized
onto microarrays according to the Affymetrix Genome-
Wide Human SNP Nsp/Sty 6.0 User Guide (revision 4).
The raw copy number data were preprocessed according
to the PennCNV protocol [57] adapted for Affymetrix
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genotyping arrays (http://www.openbioinformatics.org/
penncnv/penncnv_tutorial_affy_gw6.html) using HapMap
samples [58] as reference. Single-sample segmentation
and calculation of allele-specific and absolute DNA copy
numbers were performed using the algorithm ASCAT
(v.2.3) [59], with the penalty constant for segmentation by
the Allele-Specific Piecewise Constant Fitting algorithm
set to 50. The sex chromosomes were excluded from fur-
ther analyses.
For comparison of DNA copy number loss and gain
across samples with different segment breakpoint posi-
tions, an artificial splitting of the data into smaller seg-
ments including all breakpoint positions across the
sample set was performed. For each of these smallest re-
gions of overlap, the copy number value of the original,
larger segment was kept. Copy numbers per segment
were adjusted according to the overall ploidy of each
tumor. Regions with loss of heterozygosity (LOH) were
identified as segments with DNA copy number equal to
zero for one allele and higher than one for the other al-
lele. Copy number neutral LOH was defined as DNA
copy number equal to zero for one allele and equal to
the overall ploidy of the sample for the other allele. The
proportion of the genome affected by copy number aber-
rations (CNAs) was estimated for all samples as the per-
centage of base pairs with a total copy number different
from the overall ploidy of the sample.
Modeling of tumor clonality
Tumor clonality was modeled for the 27 MSI+ tumors
in Norwegian series I analyzed by both exome sequen-
cing and DNA copy number variation using the R pack-
age SciClone with default settings (except the threshold
for the minimum total read count set to 50) [60]. The
variant allele frequency (VAF) of each SNV and indel,
defined as the proportion (percentage) of reads of the
variant allele compared with the total number of reads
at the respective locus, was used as input, and SciClone
identified sample-wise mutation clusters (representing
genetically distinct cellular populations/subclones) based
on SNVs and indels unaffected by CNAs and LOH using
a variational Bayesian mixture model. The mutation
cluster with a mean VAF of approximately 50% of the
aberrant cell fraction (estimated using ASCAT) corre-
sponds to an early clone with pervasive heterozygous
mutations, and mutations in this clone were scored as
truncal. Mutations in clones with lower and higher mean
VAFs were scored as subclonal and homozygous, re-
spectively. The number of clones per tumor was summa-
rized from distinct mutation clusters of truncal and
subclonal mutations.
For comparison, tumor clonality was also modeled
using the R package EXPANDS [61], with maxScore set
to 1.5 and precision to 0.02. Predicted subclones
containing less than 5% of the mutations per tumor were
not considered. EXPANDS models the cellular preva-
lence of each SNV as a probability distribution based on
its VAF, adjusted for the DNA copy number at the mu-
tated locus.
Gene expression analyses
Genome-wide exon-level expression analysis was done
for a total of 73 MSI+ tumors in Norwegian series I,
including 63 of the 68 tumors analyzed for JAK1 mu-
tations, using Affymetrix GeneChip Human Exon 1.0
ST and Human Transcriptome 2.0 Arrays (Affymetrix
Inc., Santa Clara, CA, USA). These data have partly
previously been published (n = 39 samples; GSE24550,
GSE29638, and GSE69182), and the remaining sam-
ples (n = 34) have been deposited to the NCBI’s GEO
with accession number GSE79959. Raw intensity data
were background corrected, quantile normalized, and
summarized at the gene-level according to the robust
multi-array average (RMA) approach implemented in the
Affymetrix Expression Console 1.1 software. For samples
analyzed on the Affymetrix Human Transcriptome 2.0
Array, the modified Signal Space Transformation algo-
rithm of RMA was used. Gene expression data gener-
ated from the two different platforms were matched
by HUGO gene symbols and merged by batch correc-
tion using ComBat [62] implemented in the R pack-
age SVA.
Classification of the tumors according to CMS was
performed using the random forest predictor imple-
mented in the R library CMSclassifier [42]. A default
posterior probability of 0.5 was used as a threshold for
sample classification, assigning a CMS class to 61 (84%)
of the 73 tumors.
In addition, gene expression data and CMS assignments
for 65 and 75 MSI+ tumors in TCGA and GSE39582 [45],
analyzed by RNA sequencing and Affymetrix HG U133
Plus 2.0 arrays, respectively, were downloaded from the
Colorectal Cancer Subtyping Consortium web site at SAGE
Synapse (https://www.synapse.org/#!Synapse:syn2623706/
wiki/67246). Of these tumors, 64 and 69 were assigned to a
CMS class, respectively. For GSE39582, clinical data
(reporting relapse-free survival (RFS) and overall sur-
vival (OS) for 67 of the CMS classified patients) were
obtained via the GEO accession number (Additional
file 1: Table S2). Patients (n = 8 with CMS classifica-
tion) reported to have an event for OS and simultan-
eously censored for RFS were excluded from survival
analyses, due to non-compliance with the definition
of end-points used in this study [63].
Gene set expression enrichment analyses were per-
formed using the R package GSA [64] and a customized
collection of 51 gene sets relevant to CRC (Additional
file 1: Table S11). Sample-wise gene set expression
Sveen et al. Genome Medicine  (2017) 9:46 Page 5 of 16
enrichment scores were calculated using the R package
GSVA [65].
Tumor immunogenicity, evaluated based on gene ex-
pression, was analyzed by the “immunophenoscore”,
using the published R code [41]. For marker genes with
missing expression values (7 of the 162 genes on Human
Exon 1.0 arrays), imputation was done based on the
overall mean expression per sample, using the impu-
te.knn function in the R package impute. The level of in-
filtration of immune cells in the tumors was also
evaluated based on gene expression using the R packages
ESTIMATE [66] and MCPcounter v.1.1 [43]. For com-
parison with the MSI+ tumors, gene expression data
from 160 MSS tumors from Norwegian series I, included
in the previously published GEO records, were also ana-
lyzed for immune cell infiltration.
Neoantigen prediction
Mutation-associated immunogenicity was analyzed from
exome sequencing and gene expression data by compu-
tational prediction of neopeptides able to bind to
patient-specific HLA molecules. Genotyping of the indi-
vidual patients for the HLA class I genes HLA-A, B, and
C at four-digit resolution (Additional file 1: Table S3)
was done from merged sequencing BAM files of paired
tumor–normal samples for each patient using the algo-
rithm Polysolver with default settings (previously re-
ported mean overall accuracy 97%) [67]. Prior to
neopeptide prediction, the list of mutations (Additional
file 1: Table S4) was filtered sample-wise based on gene
expression, and only mutations in genes with an expres-
sion level above the median level per tumor were kept,
retaining a median of 47% of the mutations per tumor
(range 42 to 54%). All possible peptides of length 8–11
amino acids containing these mutations were predicted
using Topiary 0.0.14 (https://pypi.python.org/pypi/
topiary), with prediction of binding affinities for the
patient-specific HLA alleles using NetMHCpan 2.8 [68].
Only peptides with IC50 below 500 and a percentile rank
of predicted IC50 values across interactions between all
peptides and each HLA allele per tumor below 2 were
retained. The resulting predicted neoantigens were further
filtered to exclude peptides encoded from other, non-
mutated loci in the human genome by searching for per-
fect matches of the peptide sequences in UniProtKB re-
lease 2015_11 using the web application Peptide Match
service for UniProt Knowledgebase [69]. Lastly, to include
only peptides predicted to be generated by cleavage in
proteasomes, the list of neoantigens was filtered to include
only peptides with predicted C-terminal cleavage sites
using the stand-alone software package of NetChop 3.1
[70]. When summarizing the number of neoantigens per
tumor, peptides predicted to bind to several HLA alleles
were counted only once.
Survival analyses
Univariable and multivariable survival analyses were
conducted with Cox’s proportional hazards regression,
with calculation of P values from Wald’s tests for pre-
dictive potential using the SPSS software v.21 (IBM
Corporation, Armonk, NY, USA). Kaplan–Meier survival
curves were compared with the log-rank test. Five-year
RFS (considering relapse or death from any cause as
events, and censoring in the case of no event within five
years) and OS (time to death from any cause) were used
as endpoints, according to the definition by Punt et al.
[63]. Time to event or censoring was calculated from the
time of surgery.
Results
Molecular overview of MMR deficiency in MSI+ CRC
A total of 333 MSI+ CRCs were analyzed in the study;
an overview of the genomic analyses and results is
shown in Fig. 1 (parts a and b, respectively).
Tissue samples from 33 stage I–III MSI+ CRCs and
matched normal colonic mucosa in Norwegian series I
(Table 1) were subjected to exome sequencing with an
average depth of 273× and 109×, respectively. A total of
83,706 somatic small exonic mutations, comprising
65,880 SNVs and 17,826 indels, passed the quality filter-
ing (Additional file 1: Tables S4 and S5). The number of
amino acid-affecting mutations per tumor ranged from
957 to 4614 (median 1676; Fig. 2a), and the ratio of
amino acid-affecting mutations to synonymous SNVs
and in-frame indels was relatively consistent among the
tumors (average 2.94, standard deviation 0.25; Additional
file 1: Table S5). An MSI score representing the percent-
age of somatically unstable microsatellites per tumor
was calculated using the algorithm MSIsensor (Fig. 2b;
Additional file 1: Table S5). The MSI score was strongly
correlated with the number of indels per tumor, as
expected, but only weakly associated with the number
of SNVs (Spearman correlations 0.7 and 0.4, respectively,
P = 5 × 10−6 and 0.01; Additional file 2: Figure S1a).
Consistent with their MSI phenotype, 28 (85%) of the
tumors had methylation of the MLH1 promoter (Fig. 2c).
Compared to tumors without methylation (n = 5), this
was associated with a significant down-regulation of
MLH1 gene expression (P = 0.02 by Welch’s t-test;
Additional file 2: Figure S1b). The five tumors without
MLH1 promoter methylation had down-regulated ex-
pression of seven other known MMR genes (Additional
file 2: Figure S1c), and the sample-wise gene set enrich-
ment score for these seven genes (calculated using the R
package GSVA) was significantly lower in the unmethy-
lated compared to the methylated samples (mean differ-
ence −0.5, P = 0.05). There was no difference in the MSI
score between tumors with and without MLH1 promoter
methylation (mean MSI scores 17 and 19%, respectively,
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P = 0.2); however, lack of methylation was associated
with a younger age at diagnosis (mean age 55 years com-
pared to 77 for patients with methylation, P = 0.01). Ac-
cordingly, familial predisposition cannot be excluded, in
particular for the two youngest patients (aged 37 and
48 years).
The most common single nucleotide substitution type
was C > T/G > A transitions. Analyzing all substitutions
and their sequence context (the two flanking nucleo-
tides) across all 33 MSI+ tumors, the distribution of mu-
tations was found to correspond to mutation signature
6, as designated in COSMIC [54] (Fig. 2d). This signa-
ture is associated with hypermutation caused by MMR
deficiency and was the predominant mutation signature
also in all the tumors individually (Additional file 2:
Figure S1d). Although ten (30%) of the tumors had amino
acid-changing mutations in POLE (Additional file 1:
Table S4), none of these were in known pathogenic hot-
spots [71], and none of the tumors had a mutation signa-
ture indicative of POLE-associated hypermutation.
In contrast to SNVs and indels, the tumors displayed
few CNAs and the median proportion of the genome
affected by CNAs was 2% (Additional file 2: Figures S1e
and f; Additional file 1: Table S6).
Novel frequent frameshift indels in cancer-critical genes
In the 33 exome sequenced tumors, a total of 228 genes
were identified as significantly mutated by MutSigCV (q
values <0.05; Additional file 1: Table S7), including
PHACTR4, RPL22, TFAM, TMBIM4, TTK, VPS37B, and
WASF3 (ranked by q values). Compared to the whole ex-
ome, there was a clear enrichment for indels over SNVs
in the significantly mutated genes; the average propor-
tion of mutations that were indels was 80% among the
tumors, significantly larger than the average of 27% for
the full exome (P = 8 × 10−33, paired t-test; Additional
file 2: Figure S1g). Also among the 571 genes included
in the CGC, a modest increase in the sample-wise ra-
tio of indels to SNVs was observed (the average ratio
across the tumors was 32%), compared to the whole
exome (P = 1 × 10−6).
Among genes in the CGC, frequent frameshift indels
were detected in several genes not previously reported
to be highly mutated in CRC, including CRTC1
BRAF V600E 
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(mutation frequency 42%), BCL9 (30%), and PTCH1
(24%) (Fig. 3a). In addition, 15 of the tumors (45%) were
found to have frameshift mutations in members of the
JAK-STAT pathway (Additional file 1: Table S8). The
most commonly mutated gene was JAK1, in which 24%
of the tumors (8 of 33) had one or more single base pair
frameshift indels (Fig. 3a). For CRTC1 and BCL9, tumors
with mutations had significantly higher MSI scores than
the respective wild-type tumors (on average 4% more
unstable microsatellites; P < 0.04 for both genes by
Welch’s t-test); however, there was no significant differ-
ence in the MSI score between tumors mutated and wild
type for PTCH1 or JAK1 (P > 0.3), indicating that these
mutations are not associated with the level of tumor
hypermutation. None of the mutations were associated
with MLH1 promoter methylation (by Fisher’s exact
test). For validation, we searched for the novel frequent
frameshift mutations in publicly available exome sequen-
cing data from 66 additional MSI+ CRCs from TCGA.
The mutation frequencies of CRTC1, BCL9, JAK1, and
PTCH1 were 27, 42, 18, and 12%, respectively (Fig. 3b;
Additional file 1: Table S8).
Validation and transcriptional consequences of JAK1
loss-of-function mutations
Because of the recently suggested predictive value of
JAK1 mutations indicating resistance to anti-PD-1 treat-
ment [72, 73], this gene was selected for mutation valid-
ation analyses by PCR-based fragment analyses.
Frameshift mutations in the four hotspots identified by
exome sequencing were verified in the 33 tumors. These
hotspots were all in homopolymers upstream of the
JAK1 kinase domain (Fig. 3c), and the mutations have
previously been described as truncating, loss-of-function
mutations [74]. For an additional 149 MSI+ CRCs, JAK1
mutation frequency was 20%, both in independent
Norwegian patients (mutations in 13 of 66 tumors) and
British patients from the VICTOR trial (17 of 83)
(Fig. 3b; Additional file 1: Table S8). In summary, the
mutation frequency of JAK1 across all 248 primary
MSI+ CRCs analyzed was 20%.
JAK1 gene expression was down-regulated in MSI+
tumors in Norwegian series I with versus without JAK1
mutations (Additional file 2: Figure S2a). Gene set ex-
pression enrichment analysis also revealed a modest de-
pletion of JAK-STAT signaling in the mutated tumors
(Additional file 1: Table S9). Resistance to anti-PD-1
treatment in hypermutated tumors with JAK1 loss-of-
function mutations has been proposed to be linked to
reduced expression of the PD-L1 ligand, mediated by re-
duced signaling in the interferon gamma (IFN-γ) recep-
tor pathway [73]. In Norwegian series I, the sample-wise
enrichment scores of a six-gene IFN-γ expression signa-
ture [75] (calculated using the R package GSVA) was
significantly lower in JAK1 mutated compared to wild-
type tumors (Additional file 2: Figure S2b). Also, both
PD-1 signaling and gene expression of the PD-L1 ligand
(CD274) was significantly down-regulated in the mu-
tated tumors (Additional file 2: Figure S2c, d). To fur-
ther explore a potential association with immune
evasion, tumors were analyzed for the gene expression-
based immunophenoscore [41]. Tumors with JAK1 mu-
tations had a lower score than wild-type tumors specific-
ally for the antigen processing component (MHC score,
mean difference −0.3, P = 0.01 by Welch’s t-test), indicat-
ing immune evasion, similarly to what has been observed
in endometrial cancer [76]. The total immunophenoscore
(IPS score) was also lower in the mutated tumors (mean
difference −0.8, P = 0.08), predicting a poor response to
immune checkpoint inhibition [41]. In concordance, tu-
mors with mutations were also found to be positively
enriched for transcriptional signatures of biological pro-
cesses described to be up-regulated in melanomas with
innate resistance to anti-PD-1 treatment [40]. These pro-
cesses include epithelial-to-mesenchymal transition
(EMT), cell adhesion, extracellular matrix organization,
angiogenesis, and response to wounding; sample-wise en-
richment scores for gene signatures of all these five pro-
cesses were higher in tumors with JAK1 mutations in
both Norwegian series I and TCGA (Fig. 3d; Additional
file 1: Table S9).
Clonality of MSI+ CRCs and JAK1 mutations
Resistance to anti-PD-1 treatment is found in tumors
with homozygous, truncating JAK1 mutations (mutation
accompanied by LOH at the JAK1 locus), resulting in
complete loss of protein function [73]. To analyze the
zygosity of mutations, we did computational modeling of
tumor clonality based on the VAFs of exonic SNVs and
indels unaffected by CNAs in the 27 tumors with both
data types available, using the algorithm SciClone [60]
(Additional file 2: Figure S3a, b; Additional file 1:
Table S10). All tumors except three (89%) revealed intra-
tumor heterogeneity with more than one subclone, and
the number of clones per tumor was independent of the
number of mutations (Additional file 2: Figure S3c). The
pattern of clonality was similar among the tumors and the
majority of mutations were found to be heterozygous and
truncal (i.e., pervasive in all cancer cells in the tumor) in
all tumors except one (96% of tumors; Additional file 2:
Figure S3d). The proportion of truncal mutations in the
full exome and genes in the CGC was proportional across
the tumors, with a median of 85 and 82%, respectively
(Additional file 2: Figure S2e). For comparison, tumor
clonality was also modeled based on the algorithm
EXPANDS [61], supporting the prediction of multiple
subclones in the majority of tumors (all except one; details
in Additional file 2: Supplementary text).
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All truncating JAK1 indels were heterozygous and un-
affected by LOH (Fig. 3e), but all mutated tumors had at
least one truncal JAK1 mutation. Considering the other
genes with novel frequent frameshift mutations, BCL9
and PTCH1 mutations were also mostly heterozygous
and truncal, although one tumor had a homozygous
BCL9 mutation and both genes were found to have a
subclonal mutation in one tumor each. In contrast, mu-
tations in CRTC1 were frequently subclonal and consid-
ering both indels and SNVs, CRTC1 was indeed the
cancer-critical gene with most frequent subclonal muta-
tions (in 30% of the 27 tumors).
The mutation load of MSI+ CRCs is correlated with the
predicted neoantigen load, but not with immune cell
infiltration
To analyze the association between genetic changes and
infiltration of immune cells, the latter was evaluated
based on gene expression using the algorithm
MCPcounter [43] and the immune-score ESTIMATE
[66]. In agreement with their high mutation load, the
MSI+ tumors in Norwegian series I (n = 73) had a higher
level of infiltration of cytotoxic lymphocytes and
immune-score compared to the MSS tumors (n = 160;
Additional file 1: Figure S4a). In the exome sequenced
MSI+ tumors, neoantigens with high binding affinities
for the patient-specific class I HLA molecules were pre-
dicted from small exonic mutations in highly expressed
genes (expression level above the median across all
genes per tumor). The number of predicted neoantigens
per tumor (median 1169; range 376 to 4245) was corre-
lated to the number of exonic mutations (also including
synonymous; Spearman’s correlation 0.7, P = 4 × 10−5;
Fig. 4a). However, this relationship was not one-to-one,
indicating generation of multiple neoantigens from indi-
vidual mutations (Fig. 4b). As expected, all mutations
creating the largest numbers of neoantigens were frame-
shift indels (Additional file 2: Figure S4b), and the mean
ratios between the number of neoantigens and muta-
tions per tumor were 1.3 and 0.5 for frameshift muta-
tions and SNVs, respectively (P = 4 × 10−10 by paired
samples t-test). Still, the numbers of mutations were cor-
related to the corresponding numbers of neoantigens for
both frameshift mutations and nonsynonymous SNVs
separately (Spearman’s correlation 0.6; P = 2 × 10−4 and
P = 1 × 10−4, respectively; Additional file 2: Figure S4c).
Considering also the clonality of the mutations, a strong
correlation (Spearman 0.9; P = 7 × 10−12) between the
number of neoantigens predicted from truncal muta-
tions and the total number of mutations per tumor was
found.
Mutations predicted to be highly immunogenic were
mostly non-recurrent among the tumors (Fig. 4c).
Altogether, only 0.5 and 14.7% of the SNVs and
frameshift mutations, respectively, were predicted to cre-
ate neoantigens in more than one tumor. Mutations in
RNF43, UBR5, XYLT2, DPAGT1, REPIN1, and BRAF
(V600E) were most frequently immunogenic (in 55, 36,
30, 30, 27, and 27% of the 33 tumors, respectively).
Surprisingly, there were no associations between the
mutation load (or predicted neoantigen load) and the
level of immune cell infiltration or the immunopheno-
score among the MSI+ tumors in neither Norwegian
series I (Fig. 4d; Additional file 2: Figure S4d) nor
TCGA. Similarly, no indication of increased immune
evasion, analyzed as PD-1 signaling, was detected in
tumors with a high mutation load (Additional file 2:
Figure S4e).
There was no difference in the mutation load (or pre-
dicted neoantigen load) between tumors with and with-
out JAK1 frameshift indels (P = 0.5; Additional file 2:
Figure S4f ). However, in concordance with the observed
down-regulation of PD-1 signaling associated with JAK1
mutations, mutated tumors also had a modestly lower
level of infiltration of cytotoxic lymphocytes (analyzed
based on gene expression; P = 0.01; Additional file 2:
Figure S4g).
Immune cell infiltration is strongly associated with CMS1,
independent of JAK1 mutation status
To further explore potential correlates to immune cell
infiltration, tumors were classified according to the gene
expression-based CMS classes of CRC [42]. In
Norwegian series I, 44 (60%), 2 (3%), 12 (16%), and 3
(4%) of the MSI+ tumors were classified as CMS1,
CMS2, CMS3, and CMS4, respectively (Additional file 2:
Figure S5a). Among the exome-sequenced tumors, the
mean number of mutations was higher in CMS1 than
the other three CMS classes (1964 versus 1537 muta-
tions, respectively; P = 0.08 by Welch’s t-test; Additional
file 2: Figure S5b). This was also found among MSI+
tumors in TCGA (mean mutation load 1499 versus
1097, respectively; P = 0.03). There was no enrichment
for JAK1 mutations in any of the CMS classes (P = 0.7
by Fisher’s exact test); mutations were found in 11% of
CMS1 tumors and 18% of CMS3 tumors in Norwegian
series I (the remaining mutations were found in unclas-
sified tumors).
Gene set expression analyses revealed that the distinct
biological properties of CMS1 were recapitulated also
among MSI+ tumors only (Additional file 2: Figure S5c;
Additional file 1: Table S11). In comparison with
CMS2–4, tumors in CMS1 had a significantly higher
level of infiltration of cytotoxic lymphocytes and a
higher immune-score (ESTIMATE; Fig. 4e; Additional
file 2: Figure S5d). This was independent of JAK1 muta-
tion status, and analyzing tumors wild type for JAK1
only, CMS1 tumors still had a high level of immune cell
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infiltration (Additional file 2: Figure S5f ). Furthermore,
CMS1 tumors had strong PD-1 signaling and JAK-STAT
signaling (Fig. 4e), independent of JAK1 mutation status
(Additional file 2: Figure S5g).
JAK1 loss-of-function mutations and CMS1 are positive
prognostic factors in MSI+ CRC
Considering the substantial molecular heterogeneity and
associations with immunogenicity detected among MSI+
tumors, the distinct genomic features were investigated
for associations with patient outcome.
Among tumors analyzed for JAK1 mutations, clinical
follow-up data reporting OS were available for 175 of
the 182 Norwegian and British patients (Table 1; Fig. 1a).
Patients with a JAK1 frameshift indel (n = 36) had an OS
rate of 94%, significantly higher than the 75% OS rate of
patients wild type for JAK1 (n = 139; hazard ratio (HR)
from Cox’s regression 0.2 [95% confidence interval 0.05–
0.9], P value from Wald’s test of predictive potential
0.03; Fig. 5a). The positive prognostic association of
JAK1 mutations was seen in all the three patient series
individually (although not statistically significant;
Additional file 2: Figure S6a). In multivariable analysis,
the prognostic association was independent of patient
age (above versus below median), patient gender, and
tumor localization (right versus left and rectum; multi-
variable HR = 0.2 [0.06–1.0], P = 0.05). Furthermore, the
majority of the patients (89%; 155 of 175) were diag-
nosed with stage II or III MSI+ CRC, and the prognostic
association of JAK1 frameshift indels was independent of
cancer stage in these patients (multivariable HR = 0.1
[0.02–0.8], P = 0.03; Additional file 2: Figure S6b).
Although there was no difference in the mutation load
between tumors with and without JAK1 frameshift indels
(n = 33 patients in Norwegian series I), a large burden of
small exonic mutations (above the median; 1676 muta-
tions) was also associated with a favorable patient out-
come (Fig. 5b), independent of cancer stage (Additional
file 2: Figure S6c). In contrast, neither the MSI score nor
the clonal composition of the tumors (analyzed as the
number of subclones predicted by either SciClone or
EXPANDS) were associated with patient survival.
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The strong association between CMS1 and immune
cell infiltration suggests that CMS1 is also a favorable
prognostic factor in MSI+ CRC. Indeed, among 119 pa-
tients (with known CMS class and clinical information)
from Norwegian series I and a publicly available dataset
(GSE39582) [45], patients with CMS1 tumors (n = 91)
had a 5-year RFS rate of 81%, significantly higher than
the survival rate of 57% for patients with CMS2–4 tu-
mors (n = 28) (HR = 0.4 [0.2–0.9], P = 0.02; Fig. 5c). A
similar prognostic association was found for 5-year OS
(HR = 0.5 [0.2–1.0], P = 0.06; Additional file 2: Figure S6d).
CMS1 was associated with a better outcome than each of
the subtypes CMS2, CMS3, and CMS4 separately
(Additional file 2: Figure S6e). In a multivariable model in-
cluding patient age, gender, and cancer stage, CMS1
(versus CMS2–4) was an independent prognostic factor
(multivariable HR = 0.4 [0.2–0.9], P = 0.02; Additional
file 1: Table S12).
Combined survival analysis of CMS1 and JAK1 muta-
tions was possible for 51 patients in Norwegian series I.
Here, JAK1 mutations provided additional prognostic in-
formation to CMS1. Of note, the sample numbers in the
individual subgroups were low (four and two JAK1
mutated tumors in CMS1 and CMS2–4, respectively;
Additional file 2: Figure S6f ). However, in a multivari-
able model, the prognostic value of CMS1 (versus
CMS2–4) was statistically independent of JAK1 muta-
tions (multivariable HR = 0.2 [0.09–0.7] and 0.3 [0.1–0.9]
for 5-year RFS and OS, respectively; P = 0.007 and 0.03).
Discussion
Accurate genome-wide analysis of MSI-type indel muta-
tions has been challenging. Even in the most compre-
hensive mutational characterization studies of MSI+
CRCs published to date, scoring of indels has been lim-
ited either to known homopolymers in selected genes
[16, 20, 21] or targeted sequence alignments of a refer-
ence set of microsatellite repeats [77], or mutation call-
ing was limited to SNVs [78]. By multilevel genomics
and computational analyses, we have identified hetero-
geneity with clinical relevance within this distinct sub-
type of colorectal tumors. By exome sequencing, we
identified novel, frequent frameshift mutations in four
cancer-critical genes (CRTC1, BCL9, JAK1, and PTCH1).
The majority of mutations in CRTC1 were subclonal,
possibly explaining why these have previously gone un-
noticed, and highlighting the importance of high sequen-
cing coverage. Truncating indels in JAK1, leading to loss
of the entire kinase domain, were found in 20% of a total
of 248 tumors. In contrast, JAK1 indels have previously
been reported either as infrequent events in CRC [74] or
as specific to MSI+ tumors from the endometrium [77].
We detected frameshift mutations in 18% of MSI+ CRCs
from the dataset analyzed in the latter study (TCGA), il-
lustrating the challenge of large-scale analysis of MSI-
type mutations.
Consistent with a high level of intra-tumor heterogen-
eity and the “Big Bang model” of CRC development [79],
clonality modeling predicted several subclones in most
of the MSI+ tumors. There was no association between
tumor clonality and patient survival, which is in contrast
to reports from several other cancer types [80, 81]. On
the other hand, a favorable outcome was found among
patients with a high mutation load. As expected, the mu-
tation load was strongly correlated to the predicted
neoantigen load, and the level of immune cell infiltration
was significantly higher in MSI+ compared to MSS tu-
mors, consistent with recent results [37]. However,
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within the subgroup of MSI+ tumors, we found no asso-
ciation between the mutation load, or predicted neoanti-
gen load, and the level of immune cell infiltration. This
may be explained by technical issues, including the low
sample number and insufficient statistical power, lower
fidelity of mutation detection among hypermutated tu-
mors, and lower sensitivity of immune cell infiltration
detection based on gene expression compared to immu-
nohistochemistry. However, similar and seemingly dis-
parate results have recently been described in
melanoma. Here, the mutation load of pre-treatment bi-
opsies was associated with improved patient survival,
but not with response to anti-PD-1 treatment, which in
turn is associated with intra-tumor T-cell infiltration
[40], suggesting additional determinants of tumor im-
munogenicity. We found immune cell infiltration to be
highly dependent on the CMS class of the tumors.
CMS1 is an immunogenic subtype of CRC, associated
with a high prevalence of MSI [42, 43], and this study is,
to our knowledge, the first to describe CMS1 as a par-
ticularly immunogenic subtype also specifically among
MSI+ tumors. Clinical relevance was reinforced by a
strong association between CMS1 and patient survival.
CMS1 was originally described as a poor prognostic
factor after relapse [42]; however, among patients with
MSI+ CRC, we identify CMS1 as a favorable prognostic
factor, independent of important clinicopathological
parameters.
Positive prognostic associations were observed also for
truncating JAK1 mutations, which is in contrast to re-
cent results describing a poor outcome in patients with
skin subcutaneous melanoma, breast invasive carcinoma,
and prostate adenocarcinoma (no prognostic associa-
tions were detected in CRC in this study) [73]. These are
cancer types with a low prevalence of MSI [15], suggest-
ing heterogeneous prognostic associations according to
the mutation phenotype (MSI status). JAK-STAT signal-
ing regulates diverse cellular processes and may have
oncogenic potential [82]. Preclinical data suggest that in-
hibition of JAK1 can block colorectal tumor growth [83],
supporting a potential positive prognostic value of in-
activating mutations, but additional analyses are re-
quired to explain the role of JAK1 mutations in the
progression of MSI+ CRC. Furthermore, multivariable
analyses indicate that JAK1 mutations and CMS1 have
independent prognostic value, but combined analyses in
larger patient series are needed. Still, the promising results
observed for JAK1 mutations and CMS1 in altogether four
independent patient series reinforce the potential for mo-
lecular prognostic stratification of MSI+ CRC.
Although hypermutated tumors generally respond well
to anti-PD-1 treatment, resistance is commonly ob-
served in metastatic MSI+ CRC. Homozygous JAK1
loss-of-function mutations, resulting in an inability to
signal in the IFN-γ response pathway and with subse-
quent loss of PD-L1 expression, has been identified as
one potential resistance mechanism [73]. At the gene
expression-level, we observed similar associations with
JAK1 mutations in our series of primary MSI+ CRCs, in-
cluding up-regulation of transcriptional signatures asso-
ciated with innate resistance to anti-PD-1 treatment in
melanoma [40]. However, complete loss of JAK1 func-
tion is likely required to confer treatment resistance
[73], and clonality modeling suggested that the muta-
tions were heterozygous. We speculate that primary tu-
mors with heterozygous, truncating mutations are more
prone to biallelic inactivation and to development of re-
sistance in the metastatic setting. However, the need for
a second, inactivating hit suggests that JAK1 mutations
do not account for the majority of cases with anti-PD-1
resistance. This is supported by the favorable outcome
among patients with mutated tumors, predicting a low
mutation frequency in metastatic disease. Consequently,
there is still a need to uncover additional mechanisms of
resistance to anti-PD-1 treatment in metastatic MSI+
CRC.
Conclusions
We have identified novel frequent frameshift mutations
and molecular heterogeneity with clinical relevance in
primary MSI+ CRC. A high mutation load was found to
correlate with the predicted neoantigen load, but im-
mune cell infiltration was highest in the transcriptomic
CMS1 subgroup, and CMS1 was a predictor of a good
patient outcome. Of particular interest, considering the
potential for prediction of resistance to anti-PD-1 treat-
ment, was the validation of a high prevalence of truncat-
ing JAK1 indels in independent patient series. However,
the mutations were associated with a favorable patient
prognosis, suggesting a low mutation frequency in meta-
static disease, and reinforcing the need to discover add-
itional mechanisms of resistance to immunotherapy.
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